Evaluation of Host miRNAs as Therapeutics against Encephalitogenic Flaviviruses

Project: Research project

Project Details


DESCRIPTION (provided by applicant): The neurotropic flaviviruses, including West Nile virus (WNV) and Japanese Encephalitis virus (JEV) are mosquito borne viruses that cause significant morbidity and mortality worldwide. Unfortunately, current therapeutic options for treating disease associated with these viruses are limited. Recent studies by our group and others have demonstrated that microRNAs (miRNAs) play a major role in the life cycle of multiple viruses via regulation of both viral and host gene expression. miRNAs, therefore, represent potential targets for therapeutic intervention, either through enhancing or antagonizing their functions in virally infected cells. In this application, we propose to screen a library of miRNA analogs and antisense inhibitors to identify individual miRNAs that represent potential targets for therapeutic
intervention. Because miRNAs are expected to function by targeting gene expression of cellular mRNAs and host-cell pathways, we will identify these targets and pathways using immunoprecipitation of the RNA-induced silencing complex (RISC), bioinformatic analysis, and experimental verification. Therefore, at the completion of the R21 portion of this proposal, we expect to have identified multiple miRNAs whose activity can be modulated to inhibit WNV and JEV replication, as well as to have characterized their mechanism of action. In the R33 portion of the proposal, fully characterized miRNAs will be evaluated for therapeutic potential of identified miRNAs in a mouse model of WNV and JEV infection. PUBLIC HEALTH RELEVANCE: West Nile virus and Japanese encephalitis are major causes of viral encephalitis throughout the world. Because these viruses require multiple host-cell proteins and pathways to complete their replication cycle, we propose to develop cellular microRNAs, which themselves regulate expression of host-cell proteins and pathways, as potential therapeutics to combat these viruses.
Effective start/end date6/1/125/31/15


  • National Institutes of Health: $211,481.00
  • National Institutes of Health: $265,409.00


  • Medicine(all)
  • Immunology and Microbiology(all)


Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.